Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Recruiting · NCT07432295 · Registry updated 2026-05-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric cancer, gastric neoplasm, metastatic malignant neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-05-14 | NCT07432295 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| I-Mab Biopharma US Limited | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| I-Mab Site - 4001 | Kashiwa | Japan | 1 |
| I-Mab Site 1002 | Boston | United States | 1 |
| I-MAB Site 1005 | Duarte | United States | 1 |
| I-Mab Site 1016 | Goodyear | United States | 1 |
| I-Mab Site 2001 | Beijing | China | 1 |
| I-Mab Site 4005 | Tokyo | Japan | 1 |